Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

G. P. Murphy, S. Beckley, M. F. Brady, T. M. Chu, J. B. deKernion, C. Dhabuwala, J. F. Gaeta, R. P. Gibbons, S. A. Loening, C. F. McKiel, D. G. McLeod, J. E. Pontes, G. R. Prout, P. T. Scardino, J. U. Schlegel, J. D. Schmidt, W. W. Scott, N. H. Slack, M. S. Soloway

Research output: Contribution to journalArticle

124 Citations (Scopus)

Abstract

A prospective trial from July 1976 to September 1980 by the National Prostaitc Cancer Project randomized newly diagnosed metastatic prostate cancer patients to DES 1 mg orally three times daily or orchiectomy; or DES, 1 mg, three times daily, plus cyclophosphamide at 1 mg/m 2 iv every three weeks, or cyclophosphamide 1 g/m 2 iv every three weeks plus estramustine phosphate (Estracyt) at 600 mg/m 2 orally daily in three divided doses. There were 246 patients evaluated for response of 301 entered. These consisted of 83 on the DES/orchiectomy arm, 77 on DES plus cyclophosphamide, and 86 on Estracyt plus cyclophosphamide. Objective response rates, initially evaluated at 12 weeks, were similar among the treatments. However, chemotherapy as used in this study early in the diagnosis of metastatic disease appears to exhibit an improved effect on overall survival compared to hormone therapy alone. Analysis within groups having pain versus no pain at entry revealed a marked advantage after 80 weeks for chemotherapy when pain was initially present and a slight advantage during treatment (throughout follow-up) when the pain was absent. Median survival times were 92, 91, and 94 weeks, respectively, for the three treatments. The progression-free interval for responders showed no difference between initial treatments, although nearly one half of the patients are still in remission; hence, further follow-up will be essential. Side effects were not excessive for the chemotherapy treatment arms and patient compliance was good. This national multicenter trial provides the basis for further testing of chemotherapy agents at an earlier phase for patients with newly diagnosed metastatic prostate cancer.

Original languageEnglish
Pages (from-to)1264-1272
Number of pages9
JournalCancer
Volume51
Issue number7
DOIs
StatePublished - May 20 1983
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Estramustine
Hormones
Drug Therapy
Cyclophosphamide
Pain
Orchiectomy
Therapeutics
Survival
Patient Compliance
Multicenter Studies
Early Diagnosis
Phosphates
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. / Murphy, G. P.; Beckley, S.; Brady, M. F.; Chu, T. M.; deKernion, J. B.; Dhabuwala, C.; Gaeta, J. F.; Gibbons, R. P.; Loening, S. A.; McKiel, C. F.; McLeod, D. G.; Pontes, J. E.; Prout, G. R.; Scardino, P. T.; Schlegel, J. U.; Schmidt, J. D.; Scott, W. W.; Slack, N. H.; Soloway, M. S.

In: Cancer, Vol. 51, No. 7, 20.05.1983, p. 1264-1272.

Research output: Contribution to journalArticle

Murphy, GP, Beckley, S, Brady, MF, Chu, TM, deKernion, JB, Dhabuwala, C, Gaeta, JF, Gibbons, RP, Loening, SA, McKiel, CF, McLeod, DG, Pontes, JE, Prout, GR, Scardino, PT, Schlegel, JU, Schmidt, JD, Scott, WW, Slack, NH & Soloway, MS 1983, 'Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone', Cancer, vol. 51, no. 7, pp. 1264-1272. https://doi.org/10.1002/1097-0142(19830401)51:7<1264::AID-CNCR2820510716>3.0.CO;2-U
Murphy, G. P. ; Beckley, S. ; Brady, M. F. ; Chu, T. M. ; deKernion, J. B. ; Dhabuwala, C. ; Gaeta, J. F. ; Gibbons, R. P. ; Loening, S. A. ; McKiel, C. F. ; McLeod, D. G. ; Pontes, J. E. ; Prout, G. R. ; Scardino, P. T. ; Schlegel, J. U. ; Schmidt, J. D. ; Scott, W. W. ; Slack, N. H. ; Soloway, M. S. / Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. In: Cancer. 1983 ; Vol. 51, No. 7. pp. 1264-1272.
@article{639ad5b5b86b4f948e241432a6b3f35d,
title = "Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone",
abstract = "A prospective trial from July 1976 to September 1980 by the National Prostaitc Cancer Project randomized newly diagnosed metastatic prostate cancer patients to DES 1 mg orally three times daily or orchiectomy; or DES, 1 mg, three times daily, plus cyclophosphamide at 1 mg/m 2 iv every three weeks, or cyclophosphamide 1 g/m 2 iv every three weeks plus estramustine phosphate (Estracyt) at 600 mg/m 2 orally daily in three divided doses. There were 246 patients evaluated for response of 301 entered. These consisted of 83 on the DES/orchiectomy arm, 77 on DES plus cyclophosphamide, and 86 on Estracyt plus cyclophosphamide. Objective response rates, initially evaluated at 12 weeks, were similar among the treatments. However, chemotherapy as used in this study early in the diagnosis of metastatic disease appears to exhibit an improved effect on overall survival compared to hormone therapy alone. Analysis within groups having pain versus no pain at entry revealed a marked advantage after 80 weeks for chemotherapy when pain was initially present and a slight advantage during treatment (throughout follow-up) when the pain was absent. Median survival times were 92, 91, and 94 weeks, respectively, for the three treatments. The progression-free interval for responders showed no difference between initial treatments, although nearly one half of the patients are still in remission; hence, further follow-up will be essential. Side effects were not excessive for the chemotherapy treatment arms and patient compliance was good. This national multicenter trial provides the basis for further testing of chemotherapy agents at an earlier phase for patients with newly diagnosed metastatic prostate cancer.",
author = "Murphy, {G. P.} and S. Beckley and Brady, {M. F.} and Chu, {T. M.} and deKernion, {J. B.} and C. Dhabuwala and Gaeta, {J. F.} and Gibbons, {R. P.} and Loening, {S. A.} and McKiel, {C. F.} and McLeod, {D. G.} and Pontes, {J. E.} and Prout, {G. R.} and Scardino, {P. T.} and Schlegel, {J. U.} and Schmidt, {J. D.} and Scott, {W. W.} and Slack, {N. H.} and Soloway, {M. S.}",
year = "1983",
month = "5",
day = "20",
doi = "10.1002/1097-0142(19830401)51:7<1264::AID-CNCR2820510716>3.0.CO;2-U",
language = "English",
volume = "51",
pages = "1264--1272",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone

AU - Murphy, G. P.

AU - Beckley, S.

AU - Brady, M. F.

AU - Chu, T. M.

AU - deKernion, J. B.

AU - Dhabuwala, C.

AU - Gaeta, J. F.

AU - Gibbons, R. P.

AU - Loening, S. A.

AU - McKiel, C. F.

AU - McLeod, D. G.

AU - Pontes, J. E.

AU - Prout, G. R.

AU - Scardino, P. T.

AU - Schlegel, J. U.

AU - Schmidt, J. D.

AU - Scott, W. W.

AU - Slack, N. H.

AU - Soloway, M. S.

PY - 1983/5/20

Y1 - 1983/5/20

N2 - A prospective trial from July 1976 to September 1980 by the National Prostaitc Cancer Project randomized newly diagnosed metastatic prostate cancer patients to DES 1 mg orally three times daily or orchiectomy; or DES, 1 mg, three times daily, plus cyclophosphamide at 1 mg/m 2 iv every three weeks, or cyclophosphamide 1 g/m 2 iv every three weeks plus estramustine phosphate (Estracyt) at 600 mg/m 2 orally daily in three divided doses. There were 246 patients evaluated for response of 301 entered. These consisted of 83 on the DES/orchiectomy arm, 77 on DES plus cyclophosphamide, and 86 on Estracyt plus cyclophosphamide. Objective response rates, initially evaluated at 12 weeks, were similar among the treatments. However, chemotherapy as used in this study early in the diagnosis of metastatic disease appears to exhibit an improved effect on overall survival compared to hormone therapy alone. Analysis within groups having pain versus no pain at entry revealed a marked advantage after 80 weeks for chemotherapy when pain was initially present and a slight advantage during treatment (throughout follow-up) when the pain was absent. Median survival times were 92, 91, and 94 weeks, respectively, for the three treatments. The progression-free interval for responders showed no difference between initial treatments, although nearly one half of the patients are still in remission; hence, further follow-up will be essential. Side effects were not excessive for the chemotherapy treatment arms and patient compliance was good. This national multicenter trial provides the basis for further testing of chemotherapy agents at an earlier phase for patients with newly diagnosed metastatic prostate cancer.

AB - A prospective trial from July 1976 to September 1980 by the National Prostaitc Cancer Project randomized newly diagnosed metastatic prostate cancer patients to DES 1 mg orally three times daily or orchiectomy; or DES, 1 mg, three times daily, plus cyclophosphamide at 1 mg/m 2 iv every three weeks, or cyclophosphamide 1 g/m 2 iv every three weeks plus estramustine phosphate (Estracyt) at 600 mg/m 2 orally daily in three divided doses. There were 246 patients evaluated for response of 301 entered. These consisted of 83 on the DES/orchiectomy arm, 77 on DES plus cyclophosphamide, and 86 on Estracyt plus cyclophosphamide. Objective response rates, initially evaluated at 12 weeks, were similar among the treatments. However, chemotherapy as used in this study early in the diagnosis of metastatic disease appears to exhibit an improved effect on overall survival compared to hormone therapy alone. Analysis within groups having pain versus no pain at entry revealed a marked advantage after 80 weeks for chemotherapy when pain was initially present and a slight advantage during treatment (throughout follow-up) when the pain was absent. Median survival times were 92, 91, and 94 weeks, respectively, for the three treatments. The progression-free interval for responders showed no difference between initial treatments, although nearly one half of the patients are still in remission; hence, further follow-up will be essential. Side effects were not excessive for the chemotherapy treatment arms and patient compliance was good. This national multicenter trial provides the basis for further testing of chemotherapy agents at an earlier phase for patients with newly diagnosed metastatic prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=0020672083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020672083&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19830401)51:7<1264::AID-CNCR2820510716>3.0.CO;2-U

DO - 10.1002/1097-0142(19830401)51:7<1264::AID-CNCR2820510716>3.0.CO;2-U

M3 - Article

VL - 51

SP - 1264

EP - 1272

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7

ER -